Many of us are unhappy with our health insurers. Premiums are high. Hospital bills can be large and deductibles for many policyholders are larger than ever.
But the world looks good if you own health insurance stocks. There are profits to be made managing government health care programs — Medicaid, public exchanges, the Children's Health Insurance Program and Medicare. Because despite the confusion over health insurance, government health care expenditures continue to rise.
To wit, Medicare spending is projected grow 7.9% annually to 2023 with total expenditures of approximately $1.1 trillion. Meanwhile, Medicaid spending is estimated to grow 5.9% annually to 2023, when it will top $828 billion.
Here are five health insurance stocks to buy – all of which have advanced by double digits already in 2018. But don't worry about being late to the party. There's reason to expect more upside in these stocks because they need only to maintain a strategy at which they have proven adept: increase enrollments and contain medical costs.
Data is as of Oct. 15, 2018. Companies are listed in alphabetical order.
No one paid much attention when Centene joined the Affordable Care Act exchanges in 2014. But now it is the largest ACA player with 1.6 million marketplace members and continues to earn substantial profits from this program.
Centene is no one-trick pony, however. It wins about 81% of the Medicaid contracts it bids on, based on an analysis by Wells Fargo analysts.
Success in gaining new business has showed up on the top and bottom lines alike. Last year's earnings grew to $5.03 per share, up from $4.43 in 2016. But there's more growth to come for this health insurance stock, say Bank of America analysts, who estimate 2018 EPS of $6.95 on eye-popping revenues of $69 billion.
Humana is a well-known health insurer. Humana's balance sheet includes almost $19 billion in cash against just $5.3 billion in total debt, enabling the company to manage the twists and turns of the health care business in the U.S., and capitalize on the opportunities these twists and turns create.
Regarding the latter: In April, Humana teamed up with private equity players TPG Capital and Welsh, Carson, Anderson & Stowe to purchase hospice provider Curo for $1.4 billion. That deal followed Human's $4 billion acquisition of Kindred at Home, which when combined with Curo created the nation's largest hospice provider.
Before and shortly after CVS Health (CVS) announced its acquisition of Aetna (AET) in December of last year, there was speculation that Humana might be the next takeover target. Since then, however, that spotlight has come off Humana, and instead, the health insurance company is eyeing stronger ties with Walmart (WMT); the two companies currently have a prescription drug partnership.
While these machinations play out, Humana's Medicare Advantage continues to grow rapidly. In August, Humana raised its adjusted EPS guidance for fiscal 2018 from to approximately $14.15 from its previous range of $13.70 to $14.10. Bank of America/Merrill Lynch analysts expect Humana to benefit from a recent increase in Medicare Advantage rates.
Molina Healthcare is a managed care insurer that focuses on Medicaid. The growth in Medicaid is compelling (for insurers, but likely not for taxpayers), with government expenditures of $566 billion in 2016 projected to expand to $696 billion in 2020.
Molina reported second-quarter earnings in August that benefited from downsizing, improved productivity and debt reduction. Based on these improvements, management raised its EPS guidance substantially, from a range of $4-$4.50 per share to $7.39-$7.59, or an increase of 68%-85% on the higher and lower ends, respectively.
It's not just Medicaid spending that is fueling optimism behind Molina and similar health insurance stocks. In 2017, a management shake-up resulted in Molina's board letting go of CEO J. Mario Molina and CFO John Molina, the sons of founder C. David Molina. Joseph M. Zubretsky, former CEO of Hanover Insurance, took the reins during the fourth quarter of that year, and the company's progress under his leadership during Q1 and Q2 of this year has been material.
UnitedHealth Group is the largest health insurer in the United States, and the bulk of its business is tied to government programs that are growing at healthy rates. The stock has regularly hit new highs this year and is up 21% year-to-date.
About 10,000 baby boomers turn 65 daily and qualify for Medicare, which is UnitedHealth's largest business segment, accounting for $66 billion of its $163 billion in revenues last year. UnitedHealth's fastest-growing business, which it calls UnitedHealthcare Community & State, is tied to Medicaid spending (which is growing around 6% annually). Between 2015 and 2017, Community & State revenues jumped 29%, from $28.9 billion to $37.4 billion. These businesses are important because the employers and individual insurance division shrunk between 2016 and 2017, though it remains above 2015 levels.
Analysts are bullish on UNH because of its diversified product line, which they feel will enable it to adapt to changing government regulations and seize growth opportunities as they appear.
WellCare Health Plans
WellCare Health Plans earns most of its revenue from running Medicare programs for the government. Remember Medicare spending is growing at nearly 8%, according to the Centers for Medicare and Medical Services. Total spending in 2016 – the latest year for which actual figures are available – was $672 billion with projections for $1.1 trillion in 2023.
It's a huge pie, and Wellcare is an able, acquisitive player. The company recently completed the acquisition of several Meridian health plan companies, giving it a top market position in two states, an accretive addition to earnings — according to the company's guidance and analyst reports — and the option to enter the exchange business.
This comes on top of what Bank of America analysts forecast as robust organic growth, with 2017 earnings per share of $8.52 rising to $10.90 in 2018 – a roughly 28% improvement.